Mytbioscience
MyT Bioscience discovers potent and selective inhibitors targeting the protein kinase PKMYT1. These inhibitors are synthetically lethal in cancers driven by cyclin E, addressing significant unmet medical needs. The compounds are orally bioavailable and demonstrate potential to enhance the efficacy of DNA-damaging antibody-drug conjugates.
Traction –/10
HQ unknown
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- MyT Bioscience discovers potent and selective inhibitors targeting the protein kinase PKMYT1. These inhibitors are synthetically lethal in cancers driven by cyclin E, addressing significant unmet medical needs. The compounds are orally bioavailable and demonstrate potential to enhance the efficacy of DNA-damaging antibody-drug conjugates.